Evoke Pharma Retained Earnings (Accumulated Deficit) 2012-2024 | EVOK

Evoke Pharma retained earnings (accumulated deficit) from 2012 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Evoke Pharma Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $-123
2022 $-116
2021 $-107
2020 $-99
2019 $-86
2018 $-79
2017 $-71
2016 $-59
2015 $-48
2014 $-36
2013 $-23
2012 $-20
2011 $-18
Evoke Pharma Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-06-30 $-126
2024-03-31 $-125
2023-12-31 $-123
2023-09-30 $-121
2023-06-30 $-120
2023-03-31 $-118
2022-12-31 $-116
2022-09-30 $-114
2022-06-30 $-112
2022-03-31 $-110
2021-12-31 $-107
2021-09-30 $-106
2021-06-30 $-104
2021-03-31 $-101
2020-12-31 $-99
2020-09-30 $-97
2020-06-30 $-94
2020-03-31 $-88
2019-12-31 $-86
2019-09-30 $-84
2019-06-30 $-83
2019-03-31 $-81
2018-12-31 $-79
2018-09-30 $-77
2018-06-30 $-75
2018-03-31 $-73
2017-12-31 $-71
2017-09-30 $-71
2017-06-30 $-65
2017-03-31 $-64
2016-12-31 $-59
2016-09-30 $-57
2016-06-30 $-54
2016-03-31 $-51
2015-12-31 $-48
2015-09-30 $-45
2015-06-30 $-43
2015-03-31 $-39
2014-12-31 $-36
2014-09-30 $-33
2014-06-30 $-29
2014-03-31 $-26
2013-12-31 $-23
2013-09-30 $-21
2013-06-30 $-21
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31 $-18
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.004B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Teligent (TLGT) United States $0.000B 0.00